Dr. Chantelle Thomas

speaker

1,116 appearances 2 recordings 1 series first heard Jul 2026 last heard 30 Jul

Dr. Chantelle Thomas’s voice in public audio — every appearance, attributed to the second.

Trend

recordings per month · last 12 months

Recordings per month over the last 12 months — 2 in all, peaking in Jul 2026 with 2.

Appearances

newest first · ▶ plays the moment

RECOVERable: Mental Health and Addiction Experts Answer Your Questions · Psilocybin & Ibogaine: Can Psychedelics Cure Addiction? · 30 Jul 2026 podcast

While something quite profound could happen to someone in a setting like that, I would not say that it's anywhere close to the same thing just because the preparation that's not involved, the therapeutic support that's not alongside of it, the integration that doesn't follow.

Always trying to be really mindful of not being dismissive of the idea that profound things could happen in recreational settings, but they are very fundamentally different processes, I think, in most instances.

Well, hopefully working with these compounds over time should make us more open, not less.

And so I'm always mindful that just because the path and the lens that I use is the one that I've studied the most, that there are many different ways of working with this.

The most obvious of which is this long historical indigenous tradition that supports both of these compounds that I am a nowhere expert in.

I think that is true.

There are long-term follow-ups, but I don't actually know how much data there is on the depressive symptomatology results persisting at one year.

I think that might be the case for some people.

This is why we're studying different administrations of psilocybin because I think it was the group in the UK that did the single dose study.

I think Usona Institute also did a single dose study for a phase two trial.

But most of the psilocybin sponsors at this point in time are looking at

The indications for at least two dosages and the idea of redosing based on symptomatology.

So it's more rare, I think, that someone would have one session and then be certainly not cured of depression.

But yeah, that's part of what's being researched is persisting effects and how we might better optimize them.

Well, I've had the privilege to work at the University of Wisconsin-Madison alongside of the Protea Lab and within the School of Pharmacy on various different clinical trials, starting with a high-dose psilocybin trial pharmacokinetic study, which is basically like a physical safety study of higher-dose psilocybin to demonstrate its physical safety.

I've had the opportunity to work on depression trials with psilocybin.

both in the room but also providing support to facilitators across various sites in their training and their ongoing consultation and supervision during those trials.

I've been involved in that with the USONA Institute.

And I've also had the privilege of working on a number of trials targeting folks with substance use disorders.

So I've worked on a methamphetamine use disorder study with psilocybin and also an opiate use disorder study with psilocybin.

Showing 61–80 of 1,116 · page 4 of 56